Status:
ACTIVE_NOT_RECRUITING
Imaging Quantification of Inflammation (IQI)
Lead Sponsor:
The Cleveland Clinic
Collaborating Sponsors:
Santen Inc.
Conditions:
Uveitis
Eligibility:
All Genders
18-80 years
Brief Summary
1\. Perform observational study utilizing real-time quantification of ocular inflammation to determine minimal important change. Prospective use of changes in imaging quantification of inflammation (...
Detailed Description
1. Perform observational study utilizing real-time quantification of ocular inflammation to determine minimal important change. In our current experiments, we have calculated reliability measureme...
Eligibility Criteria
Inclusion
- Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
Exclusion
- Poor view in fundus in both eyes which precludes image acquisition in those with posterior uveitis
- Those with posterior uveitis, any allergy to fluorescein
- Corneal opacities which prevent image acquisition
- Inability to sign consent
Key Trial Info
Start Date :
September 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04704609
Start Date
September 22 2019
End Date
September 30 2027
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Foundation Cole Eye Institute
Cleveland, Ohio, United States, 44195